P
Prime Medicine, Inc. (PRME)
NGM – Real vaqt narxi. Valyuta: USD
3.30
+0.06 (1.85%)
Yopilishda: May 12, 2026, 4:00 PM EDT
3.24
-0.06 (-1.82%)
Bozor oldidan: May 13, 2026, 4:51 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
3.30
+0.06 (1.85%)
Yopilishda: May 12, 2026, 4:00 PM EDT
3.24
-0.06 (-1.82%)
Bozor oldidan: May 13, 2026, 4:51 AM EDT
Prime Medicine, Inc., biotexnologiya kompaniyasi, Qo'shma Shtatlarda genlarni tahrirlash texnologiyasidan foydalangan holda kasalliklarning butun spektrini davolash uchun genetik dori vositalarini yetkazib berish bilan shug'ullanadi. Uning asosiy terapevtik mahsuloti nomzodi - surunkali granulomatoz kasalligi uchun PM359, bu 1/2 bosqichli klinik sinovlarda; Villson kasalligi uchun PM577, bu preklinik tadqiqotlarda; va SERPINA1 genidagi mutatsiyalar natijasida yuzaga keladigan genetik buzilishlarni davolash uchun PM647, bu jigarda to'planib, jigar shikastlanishiga, sirrozga va jigar xujayrasi karsinomasining rivojlanish xavfini oshirishga olib keladigan noto'g'ri buklangan Z-AAT oqsilining ishlab chiqarilishiga olib keladi. Kompaniya jigarda uchraydigan kasalliklar va kistik fibroz dasturlarini ham taklif etadi. Bundan tashqari, u dasturlashtiriladigan DNK bog'lovchi domenlarni, shu jumladan Cas domenlarini o'z ichiga olgan Prime Editing texnologiyasini taklif etadi, ular odatda DNKda ikki tomonlama uzilishlarga olib kelmaydigan tarzda o'zgartiriladi, shuningdek, tahrirlangan DNK ketma-ketligini tahrirlash amalga oshiriladigan maqsadli genomik joyga to'g'ridan-to'g'ri nusxalaydigan RT domenini o'z ichiga oladi; va pegRNA, bu qidiruv ketma-ketligini o'z ichiga oladi, shuningdek, kosmos sifatida tanilgan, bu Prime Editor uchun maqsadli genom manzilini ta'minlaydi. Kompaniya BMS, Kistik Fibroz Jamg'armasi, Broad Instituti va Beam bilan ilmiy-tadqiqot hamkorligi va litsenziyalash shartnomasiga ega. Prime Medicine, Inc. 2019 yilda tashkil etilgan va shtab-kvartirasi Kembrij, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Allan Reine M.D. | CEO & Director |
| Dr. Andrew Anzalone M.D., Ph.D. | Co-Founder |
| Dr. Ann L. Lee Ph.D. | Chief Technical Officer |
| Dr. David R. Liu Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Dr. Keith Michael Gottesdiener M.D., Ph.D. | Consultant |
| Mr. Jeffrey D. Marrazzo M.B.A., M.P.A. | Executive Chair |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 8-K | prme-20260507.htm |
| 2026-05-07 | 10-Q | prme-20260331.htm |
| 2026-04-23 | DEFA14A | a2026proxycardnotice.htm |
| 2026-04-23 | DEF 14A | prme-20260421.htm |
| 2026-04-16 | 8-K | prme-20260407.htm |
| 2026-03-03 | POSASR | primemedicine-posasrxmarch.htm |
| 2026-03-03 | POS AM | primemedicine-posamxmarch2.htm |
| 2026-01-12 | 8-K | prme-20260112.htm |
| 2025-11-07 | S-3ASR | primemedicine-sx3asrxnovem.htm |
| 2025-11-07 | 10-Q | prme-20250930.htm |
| Mr. Mohammed Asmal M.D., Ph.D. | Chief Medical Officer |
| Mr. Ryan E. Brown J.D. | Chief Legal Officer |
| Ms. Niamh Alix | Chief Human Resources Officer |
| Ms. Svetlana Makhni | Chief Financial Officer |